Jiangsu Recbio Technology Co., Ltd. Class H
HHKEX:21793.80
HKD
+0.01
(+0.13%)
ISIN
CNE1000057K9
Return %
Stock
S&P 500
1Y
-45.71
14.20
3Y
-65.95
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Yong Liu
- Full Time Employees
- 491
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- No. 888 Yaocheng Avenue Taizhou JS China 225300
- IPO Date
- Mar 31, 2022
- Website
- recbio.cn
- Similar Companies
- Business
- Jiangsu Recbio Technology Co., Ltd. is a biopharmaceutical firm focused on the research, development, and commercialization of advanced vaccines within the People's Republic of China and for global markets. The company's pipeline emphasizes innovative candidates addressing major infectious diseases and cancer prevention. Among its lead programs is REC603, a recombinant 9-valent human papillomavirus (HPV) vaccine currently undergoing Phase III clinical evaluation in China, designed to prevent cervical cancer and genital warts. The company is also progressing recombinant HPV bivalent and quadrivalent vaccines through earlier clinical and preclinical stages. Beyond HPV, Recbio is developing ReCOV, a recombinant COVID-19 vaccine candidate which has progressed to Phase II/III trials and received Emergency Use Authorization in Mongolia. Further expanding its portfolio, the company is advancing REC610, a novel adjuvanted recombinant shingles vaccine, with its clinical trial application accepted in China and positive Phase I data from overseas. Other preclinical stage candidates include an mRNA COVID-19 vaccine, a recombinant adult tuberculosis vaccine, a virus-vectored adult tuberculosis vaccine, a recombinant influenza quadrivalent vaccine, a recombinant hand-foot-mouth disease quadrivalent vaccine, and a novel adjuvanted recombinant respiratory syncytial virus vaccine (REC625). Founded in 2011, Recbio leverages core technology platforms, including novel adjuvants, protein engineering, and immunological evaluation, to create its diverse vaccine candidates. The company has expanded its global reach through strategic partnerships, including a July 2025 licensing and technology transfer agreement with Biological E. Limited for REC603's commercialization in India and other international markets via UNICEF and PAHO tenders. Additionally, in January 2024, Recbio signed a framework agreement with SPIMACO for REC603's exclusive authorization and commercialization across 15 countries in the Middle East and North Africa region. The company is headquartered in Taizhou, People's Republic of China.